OTCMKTS:AGNPF

Algernon Pharmaceuticals News Headlines

$0.11
-0.01 (-5.76 %)
(As of 06/18/2021 03:17 PM ET)
Add
Compare
Today's Range
$0.10
$0.12
50-Day Range
$0.11
$0.15
52-Week Range
$0.10
$0.44
Volume771,200 shs
Average Volume663,323 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Algernon Pharmaceuticals (OTCMKTS AGNPF) News Headlines Today

SourceHeadline
Algernon Pharma targets first human study of psychedelic drug for Q4 2021Algernon Pharma targets first human study of psychedelic drug for Q4 2021
seekingalpha.com - June 19 at 1:46 AM
Algernon Pharmaceuticals targets first human study for its DMT stroke program in 4Q 2021Algernon Pharmaceuticals targets first human study for its DMT stroke program in 4Q 2021
proactiveinvestors.com - June 17 at 12:35 PM
Algernon Pharmaceuticals Targets First Human Study of its Psychedelic Drug DMT Stroke Program for Q4, 2021Algernon Pharmaceuticals Targets First Human Study of its Psychedelic Drug DMT Stroke Program for Q4, 2021
finance.yahoo.com - June 17 at 7:32 AM
Algernon Pharmaceuticals launches Ifenprodil Pancreatic Cancer clinical research programAlgernon Pharmaceuticals launches Ifenprodil Pancreatic Cancer clinical research program
proactiveinvestors.com - June 5 at 5:35 PM
Algernon Pharmaceuticals expands Ifenprodil research to pancreatic cancer in new clinical studyAlgernon Pharmaceuticals expands Ifenprodil research to pancreatic cancer in new clinical study
proactiveinvestors.com - June 3 at 1:09 PM
Algernon Pharmaceuticals Launches Pancreatic Cancer Clinical Research Program with IfenprodilAlgernon Pharmaceuticals Launches Pancreatic Cancer Clinical Research Program with Ifenprodil
finance.yahoo.com - June 3 at 8:08 AM
Short Interest in Algernon Pharmaceuticals Inc. (OTCMKTS:AGNPF) Grows By 24.5%Short Interest in Algernon Pharmaceuticals Inc. (OTCMKTS:AGNPF) Grows By 24.5%
americanbankingnews.com - June 2 at 5:12 AM
Algernon Pharmaceuticals points to new research at Hungary university showing potential for DMT as stroke treatmentAlgernon Pharmaceuticals points to new research at Hungary university showing potential for DMT as stroke treatment
proactiveinvestors.com - May 27 at 11:58 AM
Algernon Pharmaceuticals receives positive feedback from US FDA for its DMT stroke programAlgernon Pharmaceuticals receives positive feedback from US FDA for its DMT stroke program
proactiveinvestors.com - May 17 at 12:46 PM
Algernon Pharmaceuticals Receives Positive Feedback from U.S. FDA for Psychedelic Drug DMT Clinical Research Program for StrokeAlgernon Pharmaceuticals Receives Positive Feedback from U.S. FDA for Psychedelic Drug DMT Clinical Research Program for Stroke
finance.yahoo.com - May 17 at 7:46 AM
Algernon Pharmaceuticals reports findings from Ifenprodil Phase 2b/3 coronavirus trial may be positive for idiopathic pulmonary fibrosis (IPF) studyAlgernon Pharmaceuticals reports findings from Ifenprodil Phase 2b/3 coronavirus trial may be positive for idiopathic pulmonary fibrosis (IPF) study
proactiveinvestors.com - May 15 at 12:28 AM
Algernon Pharmaceuticals Announces Ifenprodil Reduced Interleukin 6 in Phase 2b/3 COVID StudyAlgernon Pharmaceuticals Announces Ifenprodil Reduced Interleukin 6 in Phase 2b/3 COVID Study
finance.yahoo.com - May 12 at 9:38 AM
Algernon Pharmaceuticals files end of Phase 2 meeting request with FDA for its coronavirus trial of IfenprodilAlgernon Pharmaceuticals files end of Phase 2 meeting request with FDA for its coronavirus trial of Ifenprodil
proactiveinvestors.com - April 26 at 1:06 PM
Algernon Pharmaceuticals Files End of Phase 2 Meeting Request with U.S. FDA for its COVID-19 Trial of IfenprodilAlgernon Pharmaceuticals Files End of Phase 2 Meeting Request with U.S. FDA for its COVID-19 Trial of Ifenprodil
finance.yahoo.com - April 26 at 1:06 PM
Algernon Pharmaceuticals plans meeting with the US FDA to prepare for upcoming Phase 3 Ifenprodil coronavirus trialAlgernon Pharmaceuticals plans meeting with the US FDA to prepare for upcoming Phase 3 Ifenprodil coronavirus trial
proactiveinvestors.com - April 8 at 1:53 PM
Algernon Pharmaceuticals to File End-of-Phase 2 Meeting Request with U.S. FDA for Possible Ifenprodil Phase 3 COVID-19 TrialAlgernon Pharmaceuticals to File End-of-Phase 2 Meeting Request with U.S. FDA for Possible Ifenprodil Phase 3 COVID-19 Trial
finance.yahoo.com - April 8 at 8:52 AM
Algernon Pharmaceuticals Announces Appointment of Global Expert Dr. Steven L. Wolf for DMT Stroke ProgramAlgernon Pharmaceuticals Announces Appointment of Global Expert Dr. Steven L. Wolf for DMT Stroke Program
finance.yahoo.com - April 6 at 12:39 PM
Algernon Pharmaceuticals announces topline data from Phase 2b part of its Phase 2b/3 coronavirus trial of IfenprodilAlgernon Pharmaceuticals announces topline data from Phase 2b part of its Phase 2b/3 coronavirus trial of Ifenprodil
proactiveinvestors.com - March 31 at 3:18 PM
Algernon Pharmaceuticals Announces Topline Data From its Phase 2b/3 COVID-19 Trial of IfenprodilAlgernon Pharmaceuticals Announces Topline Data From its Phase 2b/3 COVID-19 Trial of Ifenprodil
finance.yahoo.com - March 31 at 10:18 AM
Proactive news headlines including BTU metals, PlantX Life, Hill Street Beverage Company and Victory ResourcesProactive news headlines including BTU metals, PlantX Life, Hill Street Beverage Company and Victory Resources
au.finance.yahoo.com - March 29 at 5:48 PM
Algernon Pharmaceuticals and Betterlife Pharma added to the worlds first psychedelic stock ETFAlgernon Pharmaceuticals and Betterlife Pharma added to the world's first psychedelic stock ETF
proactiveinvestors.com - March 29 at 12:48 PM
Algernon Pharmaceuticals Announces its Addition to the Markets First Psychedelic Stock Index ETFAlgernon Pharmaceuticals Announces its Addition to the Market's First Psychedelic Stock Index ETF
finance.yahoo.com - March 29 at 7:48 AM
Algernon Pharmaceuticals submits pre-investigational new drug meeting request with US FDA for its DMT stroke research programAlgernon Pharmaceuticals submits pre-investigational new drug meeting request with US FDA for its DMT stroke research program
proactiveinvestors.com - March 18 at 12:48 AM
Algernon files pre-IND with FDA for direction regarding the use of DMT in stroke patientsAlgernon files pre-IND with FDA for direction regarding the use of DMT in stroke patients
proactiveinvestors.com - March 17 at 7:48 PM
Algernon Pharmaceuticals Submits U.S. FDA Pre-IND Meeting Request for Psychedelic Drug DMT Clinical Research Program for StrokeAlgernon Pharmaceuticals Submits U.S. FDA Pre-IND Meeting Request for Psychedelic Drug DMT Clinical Research Program for Stroke
finance.yahoo.com - March 17 at 9:40 AM
Algernon Pharmaceuticals updates on timing of topline results for Ifenprodil trialAlgernon Pharmaceuticals updates on timing of topline results for Ifenprodil trial
proactiveinvestors.com - March 11 at 11:04 AM
Algernon Pharmaceuticals CEO and Dr. David Nutt to Discuss DMT Stroke Clinical Research Program Featured on BioPub Webcast Hosted by Dr. KSS MD, PhDAlgernon Pharmaceuticals CEO and Dr. David Nutt to Discuss DMT Stroke Clinical Research Program Featured on BioPub Webcast Hosted by Dr. KSS MD, PhD
finance.yahoo.com - March 3 at 9:03 AM
Algernon Pharmaceuticals looks to highly regarded UK company to conduct Phase 1 DMT stroke studyAlgernon Pharmaceuticals looks to highly regarded UK company to conduct Phase 1 DMT stroke study
proactiveinvestors.com - March 2 at 7:09 PM
Algernon Pharmaceuticals to Conduct Phase 1 DMT Stroke Program Study with Hammersmith Medicines Research (UK)Algernon Pharmaceuticals to Conduct Phase 1 DMT Stroke Program Study with Hammersmith Medicines Research (UK)
finance.yahoo.com - March 1 at 12:19 PM
Algernon Pharmaceuticals Appoints VP Research & Operations and Chief Medical OfficerAlgernon Pharmaceuticals Appoints VP Research & Operations and Chief Medical Officer
finance.yahoo.com - March 1 at 7:19 AM
Algernon Pharmaceuticals updates on progress of Phase 2b final data from coronavirus trialAlgernon Pharmaceuticals updates on progress of Phase 2b final data from coronavirus trial
proactiveinvestors.com - February 17 at 2:23 PM
Algernon Pharmaceuticals Provides Update on COVID-19 Phase 2b Final Study DataAlgernon Pharmaceuticals Provides Update on COVID-19 Phase 2b Final Study Data
finance.yahoo.com - February 17 at 9:23 AM
Algernon Pharmaceuticals presents at Proactives One2One virtual investment forumAlgernon Pharmaceuticals presents at Proactive's One2One virtual investment forum
proactiveinvestors.com - February 16 at 6:42 PM
BTV News Alert Video: Algernon Pharmaceuticals Inc. - Trial Complete for COVID-19 TreatmentBTV News Alert Video: Algernon Pharmaceuticals Inc. - Trial Complete for COVID-19 Treatment
finance.yahoo.com - February 11 at 3:21 PM
Algernon Pharmaceuticals mulls lung scarring as additional endpoint for Phase 2b/3 coronavirus trial of IfenprodilAlgernon Pharmaceuticals mulls lung scarring as additional endpoint for Phase 2b/3 coronavirus trial of Ifenprodil
proactiveinvestors.com - February 10 at 11:12 PM
Algernon Pharmaceuticals considers adding lung scarring for additional endpoint in Ifenprodil studyAlgernon Pharmaceuticals considers adding lung scarring for additional endpoint in Ifenprodil study
proactiveinvestors.com - February 10 at 6:11 PM
Algernon Pharmaceuticals Considers Adding Lung Scarring as an Additional Endpoint for its Phase 2b/3 COVID-19 Study ProtocolAlgernon Pharmaceuticals Considers Adding Lung Scarring as an Additional Endpoint for its Phase 2b/3 COVID-19 Study Protocol
finance.yahoo.com - February 10 at 8:10 AM
Algernon Pharmaceuticals inks deal with Charles River Laboratories for preclinical work on DMT for strokeAlgernon Pharmaceuticals inks deal with Charles River Laboratories for preclinical work on DMT for stroke
proactiveinvestors.com - February 8 at 6:32 PM
Algernon launching research program for treatment of stroke using Psychedelic drug DMTAlgernon launching research program for treatment of stroke using Psychedelic drug DMT
proactiveinvestors.com - February 3 at 9:44 AM
Algernon CEO and CSO to Discuss New DMT Stroke Clinical Research Program Featured on BioPub Webcast Hosted by Dr. KSS MD, PhDAlgernon CEO and CSO to Discuss New DMT Stroke Clinical Research Program Featured on BioPub Webcast Hosted by Dr. KSS MD, PhD
finance.yahoo.com - February 3 at 9:44 AM
Algernon Pharmaceuticals Launches Stroke Treatment Clinical Research Program with Psychedelic Drug DMT "The Spirit Molecule"Algernon Pharmaceuticals Launches Stroke Treatment Clinical Research Program with Psychedelic Drug DMT "The Spirit Molecule"
benzinga.com - February 2 at 5:25 PM
Proactive news headlines including Algernon Pharmaceuticals, Benchmark Metals, Imagine AR Inc and Q BioMed IncProactive news headlines including Algernon Pharmaceuticals, Benchmark Metals, Imagine AR Inc and Q BioMed Inc
marketwatch.com - February 1 at 3:17 PM
Algernon Pharmaceuticals poised to investigate psychedelic compound DMT as treatment for strokeAlgernon Pharmaceuticals poised to investigate psychedelic compound DMT as treatment for stroke
proactiveinvestors.com - February 1 at 3:17 PM
Algernon Pharmaceuticals Launches Stroke Treatment Clinical Research Program with Psychedelic Drug DMT “The Spirit Molecule”Algernon Pharmaceuticals Launches Stroke Treatment Clinical Research Program with Psychedelic Drug DMT “The Spirit Molecule”
finance.yahoo.com - February 1 at 8:38 AM
Algernon Pharmaceuticals Provides Final Summary on Accelerated WarrantsAlgernon Pharmaceuticals Provides Final Summary on Accelerated Warrants
markets.businessinsider.com - January 22 at 1:04 PM
IIROC Trading Halt - AGN.WTIIROC Trading Halt - AGN.WT
markets.businessinsider.com - January 21 at 12:33 PM
Algernon Pharmaceuticals set for Phase 3 Ifenprodil coronavirus trial after go-ahead from DSMBAlgernon Pharmaceuticals set for Phase 3 Ifenprodil coronavirus trial after go-ahead from DSMB
proactiveinvestors.com - January 19 at 4:53 PM
Algernon Pharmaceuticals Receives Green Light from DSMB to Conduct Phase 3 Study of Ifenprodil for COVID-19Algernon Pharmaceuticals Receives Green Light from DSMB to Conduct Phase 3 Study of Ifenprodil for COVID-19
finance.yahoo.com - January 19 at 4:53 PM
Algernon Pharmaceuticals Provides Reminder on Expiry Date of Accelerated WarrantsAlgernon Pharmaceuticals Provides Reminder on Expiry Date of Accelerated Warrants
finance.yahoo.com - January 19 at 4:53 PM
Algernon Pharmaceuticals lead drug Ifenprodil named as potential COVID-19 treatment in European scientific journalAlgernon Pharmaceuticals lead drug Ifenprodil named as potential COVID-19 treatment in European scientific journal
proactiveinvestors.com - January 11 at 10:28 AM
This page was last updated on 6/21/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.